{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:08:01Z","timestamp":1790154481746,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Doxorubicin (Dox) resistance severely limits therapeutic efficacy in breast cancer, yet the epigenetic mechanisms linking cell-cycle control to therapy-induced cell death remain unclear. Here, we identify the histone acetyltransferase KAT8 as a critical driver of Dox resistance. Transcriptomic analysis of neoadjuvant cohorts revealed elevated KAT8 expression in residual disease (RD) tumors, which was validated in an independent cohort of 95 patients. High KAT8 levels correlated with poor therapeutic response. Mechanistically, KAT8 directly acetylated CDK1 at lysine 33 (K33) in Dox-resistant MCF-7\/ADR and MDA-MB-231\/ADR cells. K33 acetylation sustained CDK1 phosphorylation at T14, Y15, and T161, maintaining kinase activity under chemotherapeutic stress. Disruption of KAT8, either by genetic silencing or pharmacological inhibition with MG149, reduced CDK1 activation, increased mitochondrial depolarization and oxidative stress, and restored Dox sensitivity. Functionally, KAT8-dependent CDK1 K33 acetylation suppressed both apoptosis and ferroptosis, two principal Dox-induced cell death pathways. Re-expression of wild-type CDK1, but not the acetylation-deficient K33R mutant, rescued chemoresistance. In vivo, MG149 co-treatment or expression of CDK1-K33R significantly enhanced Dox-mediated tumor suppression in xenograft models without overt toxicity. Together, these findings establish KAT8-dependent CDK1 K33 acetylation as a key epigenetic mechanism sustaining anthracycline resistance and suggest that targeting the KAT8-CDK1 axis may provide a therapeutic strategy to overcome refractory breast cancer.<\/jats:p>","DOI":"10.1038\/s41419-026-09162-6","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:26:17Z","timestamp":1785723977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The KAT8-CDK1 K33 acetylation axis drives doxorubicin resistance by suppressing ferroptosis and apoptosis in breast cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Qingzhi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmeng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqing","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0048-9307","authenticated-orcid":false,"given":"Bing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-5954","authenticated-orcid":false,"given":"Jingji","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"9162_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"9162_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348.","journal-title":"N Engl J Med"},{"key":"9162_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406333","volume":"11","author":"J Chen","year":"2024","unstructured":"Chen J, Zhao D, Wang Y, Liu M, Zhang Y, Feng T, et al. Lactylated apolipoprotein C-II induces immunotherapy resistance by promoting extracellular lipolysis. Adv Sci. 2024;11:e2406333.","journal-title":"Adv Sci"},{"key":"9162_CR4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2320804121","volume":"121","author":"H Tang","year":"2024","unstructured":"Tang H, Lu YF, Zeng R, Liu C, Shu Y, Wu Y, et al. DOT1L-mediated RAP80 methylation promotes BRCA1 recruitment to elicit DNA repair. Proc Natl Acad Sci USA. 2024;121:e2320804121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9162_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.146571","volume":"322","author":"Y Tang","year":"2025","unstructured":"Tang Y, Dai C, Yang H, Yang X, Chen Z, Dou J, et al. KAT8-mediated MDH2 lactylation promotes renal cancer progression by enhancing mitochondrial function and stress resistance. Int J Biol Macromol. 2025;322:146571.","journal-title":"Int J Biol Macromol"},{"key":"9162_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101173","volume":"78","author":"C Miao","year":"2025","unstructured":"Miao C, Huang Y, Zhang C, Wang X, Wang B, Zhou X, et al. Post-translational modifications in drug resistance. Drug Resist Updat. 2025;78:101173.","journal-title":"Drug Resist Updat"},{"key":"9162_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2314128121","volume":"121","author":"B Xie","year":"2024","unstructured":"Xie B, Zhang M, Li J, Cui J, Zhang P, Liu F, et al. KAT8-catalyzed lactylation promotes eEF1A2-mediated protein synthesis and colorectal carcinogenesis. Proc Natl Acad Sci USA. 2024;121:e2314128121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9162_CR8","doi-asserted-by":"crossref","unstructured":"Bi S, Huang L, Chen Y, Hu Z, Li S, Wang Y, et al. KAT8-mediated H4K16ac is essential for sustaining trophoblast self-renewal and proliferation via regulating CDX2. Nat Commun. 2024 5602.","DOI":"10.1038\/s41467-024-49930-6"},{"key":"9162_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/path.6261","volume":"263","author":"DJ Li","year":"2024","unstructured":"Li DJ, Cheng YW, Pan JM, Guo ZC, Wang SH, Huang QF, et al. KAT8\/SIRT7-mediated Fascin-K41 acetylation\/deacetylation regulates tumor metastasis in esophageal squamous cell carcinoma. J Pathol. 2024;263:74\u201388.","journal-title":"J Pathol"},{"key":"9162_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2026.157923","volume":"153","author":"J Chu","year":"2026","unstructured":"Chu J, Zhao Q, Wang Y, Cai C, Cui X, Zhang N, et al. Ginsenoside Rg5 targets the KAT8-CISD2 axis to maintain mitochondrial homeostasis and antagonize senescence. Phytomedicine. 2026;153:157923.","journal-title":"Phytomedicine"},{"key":"9162_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41420-023-01478-y","volume":"9","author":"M Cai","year":"2023","unstructured":"Cai M, Xu S, Jin Y, Yu J, Dai S, Shi XJ, et al. hMOF induces cisplatin resistance of ovarian cancer by regulating the stability and expression of MDM2. Cell Death Discov. 2023;9:179.","journal-title":"Cell Death Discov"},{"key":"9162_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41421-023-00570-y","volume":"9","author":"Y He","year":"2023","unstructured":"He Y, Zheng CC, Yang J, Li SJ, Xu TY, Wei X, et al. Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance. Cell Discov. 2023;9:74.","journal-title":"Cell Discov"},{"key":"9162_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15:122.","journal-title":"Genome Biol"},{"key":"9162_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13578-023-01118-z","volume":"13","author":"X Xu","year":"2023","unstructured":"Xu X, Ding Y, Jin J, Xu C, Hu W, Wu S, et al. Post-translational modification of CDK1-STAT3 signaling by fisetin suppresses pancreatic cancer stem cell properties. Cell Biosci. 2023;13:176.","journal-title":"Cell Biosci"},{"key":"9162_CR15","doi-asserted-by":"publisher","first-page":"16978","DOI":"10.1074\/jbc.M109.096552","volume":"285","author":"O Timofeev","year":"2010","unstructured":"Timofeev O, Cizmecioglu O, Settele F, Kempf T, Hoffmann I. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2\/M transition. J Biol Chem. 2010;285:16978\u201390.","journal-title":"J Biol Chem"},{"key":"9162_CR16","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.1128\/MCB.23.21.7488-7497.2003","volume":"23","author":"MS Chen","year":"2003","unstructured":"Chen MS, Ryan CE, Piwnica-Worms H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol. 2003;23:7488\u201397.","journal-title":"Mol Cell Biol"},{"key":"9162_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0014-5793(93)80540-B","volume":"318","author":"R Honda","year":"1993","unstructured":"Honda R, Ohba Y, Nagata A, Okayama H, Yasuda H. Dephosphorylation of human p34cdc2 kinase on both Thr-14 and Tyr-15 by human cdc25B phosphatase. FEBS Lett. 1993;318:331\u20134.","journal-title":"FEBS Lett"},{"key":"9162_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"9162_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","volume":"65","author":"O Tacar","year":"2013","unstructured":"Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharm. 2013;65:157\u201370.","journal-title":"J Pharm Pharm"},{"key":"9162_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-026-08736-8","volume":"17","author":"YQ Yu","year":"2026","unstructured":"Yu YQ, Yu XY, Li XF, Cheng YF, Zhou YT, Mei F, et al. Extracellular ATP promotes endocrine resistance in ER+ breast cancer through upregulation of PYGL. Cell Death Dis. 2026;17:476.","journal-title":"Cell Death Dis"},{"key":"9162_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1400699","volume":"15","author":"XY Chen","year":"2024","unstructured":"Chen XY, Wu ZX, Wang JQ, Teng QX, Tang H, Liu Q, et al. Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells. Front Pharm. 2024;15:1400699.","journal-title":"Front Pharm"},{"key":"9162_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500216","volume":"20","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yang N, Yan H, Zhu Y, Zhang Q, Zhu R, et al. Novel folate-phenylfuran P-gp inhibitor conjugates for overcoming multidrug resistance in MCF-7\/ADR cell. Chem Med Chem. 2025;20:e202500216.","journal-title":"Chem Med Chem"},{"key":"9162_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202301088","volume":"10","author":"Z Kaixuan","year":"2023","unstructured":"Kaixuan Z, Weihao L, Yue W, Zifei Z, Linjie Z, Weili Z, et al. Inhibition of CDK1 overcomes oxaliplatin resistance by regulating ACSL4-mediated ferroptosis in colorectal cancer. Adv Sci. 2023;10:e2301088.","journal-title":"Adv Sci"},{"key":"9162_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.molcel.2006.11.026","volume":"24","author":"SM Sykes","year":"2006","unstructured":"Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell. 2006;24:841\u201351.","journal-title":"Mol Cell"},{"key":"9162_CR25","doi-asserted-by":"publisher","first-page":"8719","DOI":"10.3390\/ijms24108719","volume":"24","author":"W Tingting","year":"2023","unstructured":"Tingting W, Bingxin Z, Chengyu C, Yuyang C, Yujuan M, Jinmeng C, et al. The Males Absent on the First (MOF) mediated acetylation alters the protein stability and transcriptional activity of YY1 in HCT116 cells. Int J Mol Sci. 2023;24:8719.","journal-title":"Int J Mol Sci"},{"key":"9162_CR26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/CAD.0000000000001622","volume":"35","author":"Z Li","year":"2024","unstructured":"Li Z, Lu X, Zhang J, Liu T, Xu M, Liu S, et al. KAT8 enhances the resistance of lung cancer cells to cisplatin by acetylation of PKM2. Anticancer Drugs. 2024;35:732\u201340.","journal-title":"Anticancer Drugs"},{"key":"9162_CR27","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.1111\/febs.17264","volume":"291","author":"W Chen","year":"2024","unstructured":"Chen W, Chu J, Miao Y, Jiang W, Wang F, Zhang N, et al. MOF-mediated acetylation of CDK9 promotes global transcription by modulating P-TEFb complex formation. FEBS J. 2024;291:4796\u2013812.","journal-title":"FEBS J"},{"key":"9162_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13578-025-01356-3","volume":"15","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Nie G, Peng X, Zhan X, Ding D. KAT8 catalyzes the acetylation of SEPP1 at lysine 247\/249 and modulates the activity of CD8+ T cells via LRP8 to promote anti-tumor immunity in pancreatic cancer. Cell Biosci. 2025;15:24.","journal-title":"Cell Biosci"},{"key":"9162_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00407-7","volume":"7","author":"W Qiushi","year":"2023","unstructured":"Qiushi W, Tianshun MBA. Z. Targeting CDK1 in cancer: mechanisms and implications. NPJ Precis Oncol. 2023;7:58.","journal-title":"NPJ Precis Oncol"},{"key":"9162_CR30","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1091\/mbc.e11-02-0136","volume":"22","author":"C Katia","year":"2011","unstructured":"Katia C, Hugues K. P RP. Coupling of T161 and T14 phosphorylations protects cyclin B-CDK1 from premature activation. Mol Bio Cell. 2011;22:3971\u201385.","journal-title":"Mol Bio Cell"},{"key":"9162_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2026.152214","volume":"364","author":"G Liu","year":"2026","unstructured":"Liu G, Zhang Q, Zhong J, Liu Y, Chen J, Feng T, et al. The E3 ubiquitin ligase TRIM4 promotes the proliferation of glioblastoma by inhibiting ABTB1-mediated CDK1 ubiquitination. Int J Macromol. 2026;364:152214.","journal-title":"Int J Macromol"},{"key":"9162_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15308-7","volume":"11","author":"Q Li","year":"2020","unstructured":"Li Q, Qin T, Bi Z, Hong H, Ding L, Chen J, et al. Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nat Commun. 2020;11:1456.","journal-title":"Nat Commun"},{"key":"9162_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116353","volume":"173","author":"J Xu","year":"2024","unstructured":"Xu J, Zhang Z, Hu H, Yang Y, Xiao C, Xi L, et al. Synergistic antitumor effects of Peiminine and Doxorubicin on breast cancer through enhancing DNA damage via ZEB1. Biomed Pharmacother. 2024;173:116353.","journal-title":"Biomed Pharmacother"},{"key":"9162_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.14715\/cmb\/2024.70.2.24","volume":"70","author":"TN Eralp","year":"2024","unstructured":"Eralp TN, Sevinc A, Mansuroglu B. Combination therapy application of Abemaciclib with Doxorubicin in triple negative breast cancer cell line MDA-MB-231. Cell Mol Biol. 2024;70:169\u201377.","journal-title":"Cell Mol Biol"},{"key":"9162_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbrc.2018.01.016","volume":"496","author":"Z Li","year":"2018","unstructured":"Li Z, Qu M, Sun Y, Wan H, Chai F, Liu L, et al. Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases. Biochem Biophys Res Commun. 2018;496:153\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"9162_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41392-021-00667-4","volume":"6","author":"Y Liu","year":"2021","unstructured":"Liu Y, Du J, Liu X, Wang L, Han Y, Huang C, et al. MG149 inhibits histone acetyltransferase KAT8-mediated IL-33 acetylation to alleviate allergic airway inflammation and airway hyperresponsiveness. Signal Transduct Target Ther. 2021;6:321.","journal-title":"Signal Transduct Target Ther"},{"key":"9162_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.5483\/BMBRep.2022.55.10.037","volume":"55","author":"B Moon","year":"2022","unstructured":"Moon B, Park M, Cho SH, Kim KM, Seo HR, Kim JH, et al. Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells. BMB Rep. 2022;55:506\u201311.","journal-title":"BMB Rep"},{"key":"9162_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bulcan.2024.11.008","volume":"112","author":"P Sheng","year":"2025","unstructured":"Sheng P, Chen Z, Wen J, Tong C, Wang J, Du Z. MG149 suppresses anaplastic thyroid cancer progression by inhibition of lysine acetyltransferase KAT5-mediated c-Myc acetylation. Bull Cancer. 2025;112:122\u201334.","journal-title":"Bull Cancer"},{"key":"9162_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202414141","volume":"12","author":"J Yuan","year":"2025","unstructured":"Yuan J, Yang M, Wu Z, Wu J, Zheng K, Wang J, et al. The Lactate-Primed KAT8\u2012PCK2 Axis Exacerbates Hepatic Ferroptosis During Ischemia\/Reperfusion Injury by Reprogramming OXSM-dependent mitochondrial fatty acid synthesis. Adv Sci. 2025;12:e2414141.","journal-title":"Adv Sci"},{"key":"9162_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06569-x","volume":"15","author":"M Ci","year":"2024","unstructured":"Ci M, Zhao G, Li C, Liu R, Hu X, Pan J, et al. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway. Cell Death Dis. 2024;15:179.","journal-title":"Cell Death Dis"},{"key":"9162_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46358-w","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang X, Hu X, Yin J, Li W, Fu Y, Yang B, et al. Comprehensive multi-omics analysis reveals WEE1 as a synergistic lethal target with hyperthermia through CDK1 super-activation. Nat Commun. 2024;15:2089.","journal-title":"Nat Commun"},{"key":"9162_CR42","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1016\/j.molcel.2023.09.003","volume":"83","author":"YK Joo","year":"2023","unstructured":"Joo YK, Black EM, Trier I, Haakma W, Zou L, Kabeche L. ATR promotes clearance of damaged DNA and damaged cells by rupturing micronuclei. Mol Cell. 2023;83:3642\u20133658.e3644.","journal-title":"Mol Cell"},{"key":"9162_CR43","first-page":"323","volume":"4","author":"W Krek","year":"1992","unstructured":"Krek W, Nigg EA. Cell cycle regulation of vertebrate p34cdc2 activity: identification of Thr161 as an essential in vivo phosphorylation site. N Biol. 1992;4:323\u20139.","journal-title":"N Biol"},{"key":"9162_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13046-024-03047-2","volume":"43","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Xu J, Jiang Q, Yang C, Wang N, Liu X, et al. Ficolin 3 promotes ferroptosis in HCC by downregulating IR\/SREBP axis-mediated MUFA synthesis. J Exp Clin Cancer Res. 2024;43:133.","journal-title":"J Exp Clin Cancer Res"},{"key":"9162_CR45","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1002\/j.1460-2075.1991.tb04897.x","volume":"10","author":"W Krek","year":"1991","unstructured":"Krek W, Nigg EA. Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. Embo J. 1991;10:3331\u201341.","journal-title":"Embo J"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09162-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09162-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09162-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:37:37Z","timestamp":1790152657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09162-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9162"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09162-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was conducted in compliance with the principles of the Declaration of Helsinki. Informed consent was obtained from all subjects. Ethical approval for human subjects was provided by the Ethics Committee of the First Hospital of Jilin University (Approval No. 2023-395).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"825"}}